Source: International Congress 2019 – Clinical studies of asthma treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Nissen (Basel, Switzerland), M. Humbert (Paris, France), P. Gibson (Newcastle, Australia), K. Kostikas (Ioannina, Greece), X. Jaumont (Basel, Switzerland), P. Tassinari (Basel, Switzerland), P. Pfister (Basel, Switzerland), J. Bousquet (Montigny le Bretonneux, France). Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies. 2549

Member's Comments

No comment yet.

Related content which might interest you: Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 The APEX study: A retrospective review of responses of severe allergic asthma patients to omalizumab on continuous or non-continuous oral corticosteroids in UK clinical practice Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012